ClinicalTrials.gg
CompletedNCT01683058Updated Mar 31, 2015Results posted

Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

A Phase 3 interventional study of Aripiprazole IM Depot in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 38 sites in 3 countries. Open to participants aged 18 Years to 66 Years. Per ClinicalTrials.gov, last updated 2015-03-31.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
74
Allocation
Not applicable
Ages
18 Years to 66 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
80th of 125
74 · median 130
Started
2013
with 5 others
Phase 3
34 of 126
1 open now
Registered
75th of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 80th largest by enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2013, is one of 34 in phase 3, and was the 75th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 66 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The phase 3 Trial 31-12-291 is part of the aripiprazole IM depot clinical development program and has been designed to demonstrate the efficacy and safety of aripiprazole IM depot for the treatment of adults experiencing an acute relapse of schizophrenia. Subjects receive treatment during a 12-week double-blind acute treatment phase. The current trial (31-12-297) will allow the subjects who complete Trial 291 to enter this open label trial at the investigator's discretion, where additional safety and tolerability data will be collected.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 66 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects 18 to 66 years of age, inclusive, at the time of .
  • Subjects who are able to provide written informed consent (as required by IRB/IEC) prior to the initiation of any protocol-required procedures.
  • Ability, in the opinion of the investigator, to understand the nature of the trial and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, and discontinuation of prohibited concomitant medication, and to be reliably rated on assessment scales.
  • Subjects who have met the completion criteria in the 31-12-291 registrational trial for the acute treatment of adults with schizophrenia
  • Subjects who, in the investigator's judgment, require chronic treatment with antipsychotic medication and would benefit from extended treatment with an IM depot formulation.
  • Outpatient status at the Week 12 in Trial 291, with the exception of those subjects eligible to enter Trial 297 due to a positive interim analysis.

Exclusion criteria

Exclusion Criteria:

  • Sexually active males of who do not agree to practice 2 different methods of or remain abstinent during the trial and for 180 days after the last dose of trial medication. Sexually active Women of Childbearing Potential who do not agree to practice 2 different methods of birth control or remain abstinent during the trial and for 150 days after the last dose of trial medication.
  • Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving IMP in this trial.
  • Subjects experiencing acute depressive symptoms within the past 30 days, according to the investigator's opinion, that requires treatment with an antidepressant.
  • Subjects who are anticipated needing CYP2D6 or inhibitors or CYP3A4 inducers during the course of the trial.
  • Subjects with a significant risk of violent behavior; who represent a risk of committing suicide; or who in the clinical judgment of the investigator present a serious risk of suicide.
  • Subjects requiring any antipsychotic(s) other than aripiprazole IM depot after completion of Trial 291.
  • Subjects likely to require prohibited concomitant therapy during the trial
  • Laboratory test and results which are exclusionary
  • Any subject who, in the opinion of the investigator or medical monitor, should not participate in the trial
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Aripiprazole IM Depot

    Aripiprazole IM Depot 400 mg or 300 mg once monthly (every 28 days) for 24 weeks

    Drug: Aripiprazole IM Depot

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Severe TEAEs, Discontinued Investigational Medicinal Product (IMP) Due to AEs, Serious TEAEs and Outcome of Death

    A TEAE was defined as an AE that began after the first injection or was continuous from Baseline and was serious, study drug-related, or resulted in death.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Mean Change From Baseline in Suicidal Ideation Intensity Total Score by the Columbia Suicide Severity Rating Scale (C-SSRS)

    Data collected from C-SSRS were mapped into C-CASA. The Columbia Classification Algorithm of Suicide Assessment (C-CASA) method and C-SSRS(text in parentheses as said below) were mapped as; 1= completed suicide(completed suicide); 2= suicide attempt(actual attempt); 3= preparatory actions toward imminent suicidal behavior (interrupted attempt, aborted attempt and preparatory acts/behavior); 4= suicidal ideation(wish to die,active suicidal thought, active suicidal thought with method, active suicidal thought with intent,active suicidal thought with plan/intent); 5= self-injurious behavior, intent unknown; 6= not enough information: death; 7= non-suicidal self-injurious behavior(nonsuicidal self-injurious behavior); 8= other accident; psychiatric/medical; 9= not enough information/non-death. C-CASA category 5, 6, 8 and 9 are not applicable. For each item, each participant received an intensity score from 0(none) to 5(worst). Suicidal ideation intensity total score range from 0 to 25.

    Time frame: Baseline to Week 24

  2. Mean Change From Baseline by Week by Extrapyramidal Symptoms (EPS) Evaluated Using the Simpson-Angus Scale (SAS)

    The EPS rating scales included SAS total score (range 10-50) was the sum of the rating scores for 10 items from the SAS panel. This scale consists of a list of 10 symptoms, each to be rated on a 5-point scale of severity. For each symptom, the rating which best described the patient's condition were, 1= gait; 2= arm dropping; 3= shoulder shaking; 4= elbow rigidity; 5= wrist rigidity; 6= head rotation; 8= tremor; 9= salivation; 10= akathisia.

    Time frame: Baseline to Week 24

  3. Mean Change From Baseline by Week by EPS Evaluated Using the Abnormal Involuntary Movement Scale (AIMS)

    EPS rating scale included the AIMS movement rating score (range 0-28) was the sum of the rating scores for facial and oral movements (i.e., item 1 - 4), extremity movements (i.e. item 5 - 6), and trunk movements (i.e. item 7). The symptoms for facial and oral movements were 1= muscles of facial expression, 2= lips and perioral area, 3= jaw and 4=tongue; extremity movements were, 5= upper (arms, wrists, hands, fingers), lower (legs, knees, ankles, toes), 7= neck, shoulders, hips). This scale consisted of 10 items, each to be rated on a 4-point scale of severity, and 2 questions to be answered by yes or no. To complete the scale, the patient was observed unobtrusively at rest (e.g., in waiting room). The chair used for this examination was hard, firm one without arms.

    Time frame: Baseline to Week 24

  4. Mean Change From Baseline by Week by EPS Evaluated Using Barnes Akathisia Rating Scale (BARS)

    The BARS global score (range 0-5) was derived from the global clinical assessment of akathisia from the BARS panel were, 0= absent; 1= questionable; 2= mild akathisia; 3= moderate akathisia; 4= marked akathisia; 5= severe akathisia. Patients were observed while they were seated and then standing (for a minimum of 2 minutes in each position). Symptoms were observed in other situations (e.g., while engaged in neutral conversation, engaged in activity on the ward) was also rated.

    Time frame: Baseline to Week 24

  5. Mean Change in Body Temperature From Baseline in All Participants.

    The body temperature, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, and respiratory rate that were identified based on pre-defined criteria.

    Time frame: Baseline to last visit

  6. Mean Change in Heart Rate Supine From Baseline in All Participants.

    The heart rate supine, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, and respiratory rate that were identified based on pre-defined criteria.

    Time frame: Baseline to last visit

  7. Mean Change in Systolic Supine Blood Pressure (BP) From Baseline in All Participants.

    The systolic supine BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, and respiratory rate that were identified based on pre-defined criteria.

    Time frame: Baseline to last visit

  8. Mean Change in Diastolic Supine BP From Baseline in All Participants.

    The diastolic supine BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria.

    Time frame: Baseline to last visit

  9. Mean Change in Heart Rate From Baseline in All Participants.

    The heart rate sitting, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant was supine for at least 5 minutes and again after the participant was sitting for approximately 2 minutes.

    Time frame: Baseline to last visit

  10. Mean Change in Systolic BP From Baseline in All Participants.

    The systolic sitting BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant was supine for at least 5 minutes and again after the participant was sitting for approximately 2 minutes.

    Time frame: Baseline to last visit

  11. Mean Change in Diastolic BP From Baseline in All Participants.

    The diastolic sitting BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant was supine for at least 5 minutes and again after the participant was sitting for approximately 2 minutes.

    Time frame: Baseline to last visit

  12. Mean Change in Ventricular Rate From Baseline in All Participants.

    The measurement ventricular rate is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

    Time frame: Baseline to last visit

  13. Mean Change in PR Interval From Baseline in All Participants.

    The measurement PR interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

    Time frame: Baseline to last visit

  14. Mean Change in RR Interval From Baseline in All Participants.

    The measurement RR interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

    Time frame: Baseline to last visit

  15. Mean Change in QRS Interval From Baseline in All Participants.

    The measurement QRS interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

    Time frame: Baseline to last visit

  16. Mean Change in QT Interval From Baseline in All Participants.

    The measurement QT interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

    Time frame: Baseline to last visit

  17. Mean Change in QTcB Interval From Baseline in All Participants.

    The measurement QTcB interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

    Time frame: Baseline to last visit

  18. Mean Change in QTcF Interval From Baseline in All Participants.

    The measurement QTcF interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

    Time frame: Baseline to last visit

  19. Mean Change in QTcN Interval From Baseline in All Participants.

    The measurement QTcN interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

    Time frame: Baseline to last visit

  20. Mean Change in Clinically Relevant Body Weight Changes From Baseline in All Participants.

    Clinically relevant body weight changes was one of the primary parameters to measure the safety and tolerability of individual participants. Each participant's body mass index (BMI) kilogram per square meter (kg/m2) were calculated from the screening. Body weight, BMI, and waist circumference changes were evaluated by calculating mean change from Baseline and by tabulating the incidence of ≥7% weight gain or loss.

    Time frame: Baseline to last visit

  21. Mean Change in Clinically Relevant Body Mass Index From Baseline in All Participants.

    Clinically relevant body mass index was one of the primary parameters to measure the safety and tolerability of individual participants. Each participant's body mass index (BMI) kilogram per square meter (kg/m2) were calculated from the screening. Body weight, BMI, and waist circumference changes were evaluated by calculating mean change from Baseline and by tabulating the incidence of ≥7% weight gain or loss.

    Time frame: Baseline to last visit

  22. Mean Change in Clinically Relevant Waist Circumference From Baseline in All Participants.

    Clinically relevant waist circumference was one of the primary parameters to measure the safety and tolerability of individual participants. Each participant's body mass index (BMI) kilogram per square meter (kg/m2) were calculated from the screening. Body weight, BMI, and waist circumference changes were evaluated by calculating mean change from Baseline and by tabulating the incidence of ≥7% weight gain or loss.

    Time frame: Baseline to last visit

  23. Number of Participants With Clinically Relevant Laboratory Values.

    The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria.

    Time frame: Baseline to last visit

  24. Number of Participants With Clinically Relevant Physical Examination.

    The physical examination evaluation was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in the following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae.

    Time frame: Baseline to last visit

07

Results

Posted Mar 31, 2015

Participant flow

A multicenter, open-label, single-arm rollover trial designed to demonstrate the safety of aripiprazole intramuscular (IM) depot \[400 or 300 milligrams (mg)\] for the acute treatment of participants with schizophrenia, who met completion criteria in the registration trial NCT01663532. 74 participants were enrolled in this trial.

Participant flow — Overall Study
MilestoneAripiprazole IM Depot 400/300 mg
Started74
Completed45
Not completed29
Withdrew: Lost to follow-up9
Withdrew: Adverse event6
Withdrew: Subject met withdrawal criteria5
Withdrew: Withdrawal by subject7
Withdrew: Lack of efficacy2

Outcome measures

PrimaryPercentage of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Severe TEAEs, Discontinued Investigational Medicinal Product (IMP) Due to AEs, Serious TEAEs and Outcome of Death

A TEAE was defined as an AE that began after the first injection or was continuous from Baseline and was serious, study drug-related, or resulted in death.

Time frame:
Baseline to Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Severe TEAEs, Discontinued Investigational Medicinal Product (IMP) Due to AEs, Serious TEAEs and Outcome of Death
Percentage of participantsAripiprazole IM Depot 400/300 mg
Participants with TEAEs66.2
Participants with serious TEAEs6.8
Participants with severe TEAEs8.1
Participants discontinued IMP due to AEs8.1
Deaths0.0
SecondaryMean Change From Baseline in Suicidal Ideation Intensity Total Score by the Columbia Suicide Severity Rating Scale (C-SSRS)

Data collected from C-SSRS were mapped into C-CASA. The Columbia Classification Algorithm of Suicide Assessment (C-CASA) method and C-SSRS(text in parentheses as said below) were mapped as; 1= completed suicide(completed suicide); 2= suicide attempt(actual attempt); 3= preparatory actions toward imminent suicidal behavior (interrupted attempt, aborted attempt and preparatory acts/behavior); 4= suicidal ideation(wish to die,active suicidal thought, active suicidal thought with method, active suicidal thought with intent,active suicidal thought with plan/intent); 5= self-injurious behavior, intent unknown; 6= not enough information: death; 7= non-suicidal self-injurious behavior(nonsuicidal self-injurious behavior); 8= other accident; psychiatric/medical; 9= not enough information/non-death. C-CASA category 5, 6, 8 and 9 are not applicable. For each item, each participant received an intensity score from 0(none) to 5(worst). Suicidal ideation intensity total score range from 0 to 25.

Time frame:
Baseline to Week 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Suicidal Ideation Intensity Total Score by the Columbia Suicide Severity Rating Scale (C-SSRS)
Units on a scaleAripiprazole IM Depot 400/300 mg
Week 4 (N= 69)-0.1 ± 2.3
Week 8 (N= 61)-0.1 ± 2.2
Week 12 (N= 57)-0.3 ± 2.0
Week 16 (N= 52)0.7 ± 4.7
Week 20 (N= 44)0.3 ± 2.0
Week 24 (N= 45)0.0 ± 0.0
Last Visit (N= 71)0.6 ± 4.2
SecondaryMean Change From Baseline by Week by Extrapyramidal Symptoms (EPS) Evaluated Using the Simpson-Angus Scale (SAS)

The EPS rating scales included SAS total score (range 10-50) was the sum of the rating scores for 10 items from the SAS panel. This scale consists of a list of 10 symptoms, each to be rated on a 5-point scale of severity. For each symptom, the rating which best described the patient's condition were, 1= gait; 2= arm dropping; 3= shoulder shaking; 4= elbow rigidity; 5= wrist rigidity; 6= head rotation; 8= tremor; 9= salivation; 10= akathisia.

Time frame:
Baseline to Week 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline by Week by Extrapyramidal Symptoms (EPS) Evaluated Using the Simpson-Angus Scale (SAS)
Units on a scaleAripiprazole IM Depot 400/300 mg
Week 12 (N= 66)0.19 ± 1.51
Week 24 (N= 70)0.04 ± 1.62
SecondaryMean Change From Baseline by Week by EPS Evaluated Using the Abnormal Involuntary Movement Scale (AIMS)

EPS rating scale included the AIMS movement rating score (range 0-28) was the sum of the rating scores for facial and oral movements (i.e., item 1 - 4), extremity movements (i.e. item 5 - 6), and trunk movements (i.e. item 7). The symptoms for facial and oral movements were 1= muscles of facial expression, 2= lips and perioral area, 3= jaw and 4=tongue; extremity movements were, 5= upper (arms, wrists, hands, fingers), lower (legs, knees, ankles, toes), 7= neck, shoulders, hips). This scale consisted of 10 items, each to be rated on a 4-point scale of severity, and 2 questions to be answered by yes or no. To complete the scale, the patient was observed unobtrusively at rest (e.g., in waiting room). The chair used for this examination was hard, firm one without arms.

Time frame:
Baseline to Week 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline by Week by EPS Evaluated Using the Abnormal Involuntary Movement Scale (AIMS)
Units on a scaleAripiprazole IM Depot 400/300 mg
Week 12 (N= 65)-0.06 ± 0.81
Week 24 (N= 70)0.07 ± 1.28
SecondaryMean Change From Baseline by Week by EPS Evaluated Using Barnes Akathisia Rating Scale (BARS)

The BARS global score (range 0-5) was derived from the global clinical assessment of akathisia from the BARS panel were, 0= absent; 1= questionable; 2= mild akathisia; 3= moderate akathisia; 4= marked akathisia; 5= severe akathisia. Patients were observed while they were seated and then standing (for a minimum of 2 minutes in each position). Symptoms were observed in other situations (e.g., while engaged in neutral conversation, engaged in activity on the ward) was also rated.

Time frame:
Baseline to Week 24
Reported as:
Mean · Units on a scale
Mean Change From Baseline by Week by EPS Evaluated Using Barnes Akathisia Rating Scale (BARS)
Units on a scaleAripiprazole IM Depot 400/300 mg
Week 12 (N= 65)0.19 ± 0.73
Week 24 (N= 70)0.14 ± 0.91
SecondaryMean Change in Body Temperature From Baseline in All Participants.

The body temperature, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, and respiratory rate that were identified based on pre-defined criteria.

Time frame:
Baseline to last visit
Reported as:
Mean · °C
Mean Change in Body Temperature From Baseline in All Participants.
°CAripiprazole IM Depot 400/ 300 mg
Week 4 (N= 69)0.1 ± 0.4
Week 8 (N= 61)-0.0 ± 0.4
Week 12 (N= 58)0.0 ± 0.4
Week 16 (N= 53)0.0 ± 0.3
Week 20 (N= 44)0.1 ± 0.4
Week 24 (N= 45)0.1 ± 0.4
Last visit (N= 72)0.0 ± 0.4
SecondaryMean Change in Heart Rate Supine From Baseline in All Participants.

The heart rate supine, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, and respiratory rate that were identified based on pre-defined criteria.

Time frame:
Baseline to last visit
Reported as:
Mean · beats/min
Mean Change in Heart Rate Supine From Baseline in All Participants.
beats/minAripiprazole IM Depot 400/ 300 mg
Week 4 (N= 69)3.8 ± 10.9
Week 8 (N= 61)2.3 ± 11.2
Week 12 (N= 58)1.3 ± 10.8
Week 16 (N= 53)4.7 ± 12.0
Week 20 (N= 44)3.6 ± 9.8
Week 24 (N= 45)1.7 ± 12.7
Last visit (N= 72)3.4 ± 12.1
SecondaryMean Change in Systolic Supine Blood Pressure (BP) From Baseline in All Participants.

The systolic supine BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure, and respiratory rate that were identified based on pre-defined criteria.

Time frame:
Baseline to last visit
Reported as:
Mean · mmHg
Mean Change in Systolic Supine Blood Pressure (BP) From Baseline in All Participants.
mmHgAripiprazole IM Depot 400/ 300 mg
Week 4 (N= 69)1.9 ± 12.8
Week 8 (N= 61)1.3 ± 12.2
Week 12 (N= 58)-0.2 ± 12.4
Week 16 (N= 53)2.0 ± 12.4
Week 20 (N= 44)4.8 ± 12.8
Week 24 (N= 45)0.7 ± 11.3
Last visit (N= 72)0.4 ± 13.1
SecondaryMean Change in Diastolic Supine BP From Baseline in All Participants.

The diastolic supine BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria.

Time frame:
Baseline to last visit
Reported as:
Mean · mmHg
Mean Change in Diastolic Supine BP From Baseline in All Participants.
mmHgAripiprazole IM Depot 400/ 300 mg
Week 4 (N= 69)0.1 ± 8.6
Week 8 (N= 61)-1.3 ± 8.1
Week 12 (N= 58)-0.9 ± 7.7
Week 16 (N= 53)0.3 ± 8.6
Week 20 (N= 44)-0.0 ± 9.6
Week 24 (N= 45)0.4 ± 9.7
Last visit (N= 72)0.5 ± 9.9
SecondaryMean Change in Heart Rate From Baseline in All Participants.

The heart rate sitting, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant was supine for at least 5 minutes and again after the participant was sitting for approximately 2 minutes.

Time frame:
Baseline to last visit
Reported as:
Mean · beats/min
Mean Change in Heart Rate From Baseline in All Participants.
beats/minAripiprazole IM Depot 400/ 300 mg
Week 4 (N= 69)1.2 ± 9.1
Week 8 (N= 61)1.4 ± 10.1
Week 12 (N= 58)-1.1 ± 10.8
Week 16 (N= 53)4.3 ± 12.0
Week 20 (N= 44)3.3 ± 10.1
Week 24 (N= 45)0.6 ± 13.6
Last visit (N= 72)1.9 ± 13.0
SecondaryMean Change in Systolic BP From Baseline in All Participants.

The systolic sitting BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant was supine for at least 5 minutes and again after the participant was sitting for approximately 2 minutes.

Time frame:
Baseline to last visit
Reported as:
Mean · mmHg
Mean Change in Systolic BP From Baseline in All Participants.
mmHgAripiprazole IM Depot 400/ 300 mg
Week 4 (N= 69)-0.1 ± 13.0
Week 8 (N= 61)-0.3 ± 11.3
Week 12 (N= 58)-0.7 ± 11.3
Week 16 (N= 53)1.6 ± 12.1
Week 20 (N= 44)1.0 ± 11.5
Week 24 (N= 45)-0.4 ± 12.5
Last visit (N= 72)-0.7 ± 13.4
SecondaryMean Change in Diastolic BP From Baseline in All Participants.

The diastolic sitting BP, which is a vital sign parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of treatment-emergent adverse events of potential clinical relevance included abnormal values in body temperature, heart rate, systolic and diastolic blood pressure and respiratory rate that were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant was supine for at least 5 minutes and again after the participant was sitting for approximately 2 minutes.

Time frame:
Baseline to last visit
Reported as:
Mean · mmHg
Mean Change in Diastolic BP From Baseline in All Participants.
mmHgAripiprazole IM Depot 400/ 300 mg
Week 4 (N= 69)-0.9 ± 9.7
Week 8 (N= 61)-1.7 ± 9.4
Week 12 (N= 58)-0.2 ± 7.9
Week 16 (N= 53)0.8 ± 7.8
Week 20 (N= 44)-0.2 ± 10.0
Week 24 (N= 45)0.4 ± 9.8
Last visit (N= 72)1.4 ± 10.0
SecondaryMean Change in Ventricular Rate From Baseline in All Participants.

The measurement ventricular rate is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

Time frame:
Baseline to last visit
Reported as:
Mean · Beats/min
Mean Change in Ventricular Rate From Baseline in All Participants.
Beats/minAripiprazole IM Depot 400/ 300 mg
Week 12 (N= 56)-1.5 ± 12.0
Week 24 (N= 43)-1.1 ± 12.3
Last visit (N= 70)-0.1 ± 13.7
SecondaryMean Change in PR Interval From Baseline in All Participants.

The measurement PR interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

Time frame:
Baseline to last visit
Reported as:
Mean · msec
Mean Change in PR Interval From Baseline in All Participants.
msecAripiprazole IM Depot 400/ 300 mg
Week 12 (N= 56)3.5 ± 11.1
Week 24 (N= 43)0.5 ± 12.5
Last visit (N= 70)0.9 ± 11.6
SecondaryMean Change in RR Interval From Baseline in All Participants.

The measurement RR interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

Time frame:
Baseline to last visit
Reported as:
Mean · msec
Mean Change in RR Interval From Baseline in All Participants.
msecAripiprazole IM Depot 400/ 300 mg
Week 12 (N= 56)23.7 ± 140.9
Week 24 (N= 43)23.3 ± 152.2
Last visit (N= 70)8.0 ± 158.4
SecondaryMean Change in QRS Interval From Baseline in All Participants.

The measurement QRS interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

Time frame:
Baseline to last visit
Reported as:
Mean · msec
Mean Change in QRS Interval From Baseline in All Participants.
msecAripiprazole IM Depot 400/ 300 mg
Week 12 (N= 56)-0.1 ± 5.0
Week 24 (N= 43)0.4 ± 5.3
Last visit (N= 70)0.0 ± 5.7
SecondaryMean Change in QT Interval From Baseline in All Participants.

The measurement QT interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

Time frame:
Baseline to last visit
Reported as:
Mean · msec
Mean Change in QT Interval From Baseline in All Participants.
msecAripiprazole IM Depot 400/ 300 mg
Week 12 (N= 56)3.1 ± 21.5
Week 24 (N= 43)1.5 ± 24.9
Last visit (N= 70)1.0 ± 25.7
SecondaryMean Change in QTcB Interval From Baseline in All Participants.

The measurement QTcB interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

Time frame:
Baseline to last visit
Reported as:
Mean · msec
Mean Change in QTcB Interval From Baseline in All Participants.
msecAripiprazole IM Depot 400/ 300 mg
Week 12 (N= 56)-1.6 ± 20.2
Week 24 (N= 43)-2.4 ± 19.4
Last visit (N= 70)0.3 ± 19.0
SecondaryMean Change in QTcF Interval From Baseline in All Participants.

The measurement QTcF interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

Time frame:
Baseline to last visit
Reported as:
Mean · msec
Mean Change in QTcF Interval From Baseline in All Participants.
msecAripiprazole IM Depot 400/ 300 mg
Week 12 (N= 56)-0.2 ± 13.9
Week 24 (N= 43)-1.3 ± 14.0
Last visit (N= 70)0.3 ± 12.9
SecondaryMean Change in QTcN Interval From Baseline in All Participants.

The measurement QTcN interval is an ECG parameter were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in heart rate and ECG intervals of PR, RR, QRS, QT, QTcB, QTcN and QTcF that were identified based on pre-defined criteria.

Time frame:
Baseline to last visit
Reported as:
Mean · msec
Mean Change in QTcN Interval From Baseline in All Participants.
msecAripiprazole IM Depot 400/ 300 mg
Week 12 (N= 56)-0.5 ± 14.7
Week 24 (N= 43)-1.7 ± 14.3
Last visit (N= 70)0.3 ± 13.4
SecondaryMean Change in Clinically Relevant Body Weight Changes From Baseline in All Participants.

Clinically relevant body weight changes was one of the primary parameters to measure the safety and tolerability of individual participants. Each participant's body mass index (BMI) kilogram per square meter (kg/m2) were calculated from the screening. Body weight, BMI, and waist circumference changes were evaluated by calculating mean change from Baseline and by tabulating the incidence of ≥7% weight gain or loss.

Time frame:
Baseline to last visit
Reported as:
Mean · Kg
Mean Change in Clinically Relevant Body Weight Changes From Baseline in All Participants.
KgAripiprazole IM Depot 400/ 300 mg
Week 12 (N= 57)-0.1 ± 4.5
Week 24 (N= 44)1.3 ± 6.0
Last visit (N= 71)0.5 ± 5.8
SecondaryMean Change in Clinically Relevant Body Mass Index From Baseline in All Participants.

Clinically relevant body mass index was one of the primary parameters to measure the safety and tolerability of individual participants. Each participant's body mass index (BMI) kilogram per square meter (kg/m2) were calculated from the screening. Body weight, BMI, and waist circumference changes were evaluated by calculating mean change from Baseline and by tabulating the incidence of ≥7% weight gain or loss.

Time frame:
Baseline to last visit
Reported as:
Mean · Kg/m2
Mean Change in Clinically Relevant Body Mass Index From Baseline in All Participants.
Kg/m2Aripiprazole IM Depot 400/ 300 mg
Week 12 (N= 57)-0.0 ± 1.5
Week 24 (N= 44)0.5 ± 2.0
Last visit (N= 71)0.2 ± 1.9
SecondaryMean Change in Clinically Relevant Waist Circumference From Baseline in All Participants.

Clinically relevant waist circumference was one of the primary parameters to measure the safety and tolerability of individual participants. Each participant's body mass index (BMI) kilogram per square meter (kg/m2) were calculated from the screening. Body weight, BMI, and waist circumference changes were evaluated by calculating mean change from Baseline and by tabulating the incidence of ≥7% weight gain or loss.

Time frame:
Baseline to last visit
Reported as:
Mean · cm
Mean Change in Clinically Relevant Waist Circumference From Baseline in All Participants.
cmAripiprazole IM Depot 400/ 300 mg
Week 24 (N= 44)1.6 ± 6.6
Last visit (N= 64)1.3 ± 6.0
SecondaryNumber of Participants With Clinically Relevant Laboratory Values.

The laboratory values were one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria.

Time frame:
Baseline to last visit
Reported as:
Number · participants
Number of Participants With Clinically Relevant Laboratory Values.
participantsAripiprazole IM Depot 400/ 300 mg
Number of Participants With Clinically Relevant Laboratory Values.0
SecondaryNumber of Participants With Clinically Relevant Physical Examination.

The physical examination evaluation was one of the primary parameters to measure the safety and tolerability of individual participants. Incidence of TEAEs of potential clinical relevance include abnormal changes in the following body systems: head, ears, eyes, nose, and throat; thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae.

Time frame:
Baseline to last visit
Reported as:
Number · participants
Number of Participants With Clinically Relevant Physical Examination.
participantsAripiprazole IM Depot 400/ 300 mg
Number of Participants With Clinically Relevant Physical Examination.0

Adverse events

Collected over AEs were recorded from the time the ICF was signed until follow-up for safety 14 (±2) days after the last trial visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole IM Depot 400/300 mg—5/74 (6.8%)40/74 (54.1%)
Most frequent serious events
Most frequent serious events
EventAripiprazole IM Depot 400/300 mg
DepressionPsychiatric disorders2/74
SchizophreniaPsychiatric disorders2/74
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/74
Suicidal ideationPsychiatric disorders1/74
Most frequent other events
Most frequent other events
EventAripiprazole IM Depot 400/300 mg
Weight increasedInvestigations22/74
AkathisiaNervous system disorders9/74
Weight decreasedInvestigations6/74
HeadacheNervous system disorders6/74
HyperlipidaemiaMetabolism and nutrition disorders4/74

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aripiprazole IM Depot 400/300 mg
Mean43.0 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole IM Depot 400/300 mg
Female18
Male56
08

Study locations

38 sites
  • Little Rock, Arkansas 72201, United States
  • Springdale, Arkansas 72764, United States
  • Carson, California 90746, United States
  • Escondido, California 92025, United States
  • Garden Grove, California 92845, United States
  • Long Beach, California 90813, United States
  • National City, California 91950, United States
  • Oakland, California 94612, United States
  • Pico Rivera, California 90660, United States
  • San Diego, California 92102, United States
  • San Diego, California 92123, United States
  • Santa Ana, California 92701, United States
  • Sherman Oaks, California 91403, United States
  • Washington, District of Columbia 20016, United States
  • Fort Lauderdale, Florida 33334, United States
  • Ft. Lauderdale, Florida 33301, United States
  • Ft. Lauderdale, Florida 33308, United States
  • Kissimmee, Florida 34741, United States
  • North Miami, Florida 33162, United States
  • Orlando, Florida 32810, United States
  • Atlanta, Georgia 30308, United States
  • Hoffman Estates, Illinois 60169, United States
  • Lake Charles, Louisiana 70629, United States
  • Flowood, Mississippi 39232, United States
  • St Louis, Missouri 63128, United States
  • St. Louis, Missouri 63118, United States
  • Marlton, New Jersey 08053, United States
  • Holliswood, New York 11423, United States
  • Dayton, Ohio 45417, United States
  • Philadelphia, Pennsylvania 19139, United States
  • Austin, Texas 78731, United States
  • Austin, Texas 78754, United States
  • Dallas, Texas 75231, United States
  • Dallas, Texas 75243, United States
  • Houston, Texas 77007, United States
  • Popovaca, 44317, Croatia
  • Zagreb, 10090, Croatia
  • Daugavpils, LV-5417, Latvia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2012
First posted
Sep 11, 2012
Start
Jan 2013
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Mar 31, 2015
Last update
Mar 31, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01683058
Responsible party
Sponsor
First posted
Sep 11, 2012
Start date
Jan 2013
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Mar 31, 2015
Last update
Mar 31, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion